BCL-2 inhibition has been shown to be effective in acute myeloid leukemia (AML) in combination with hypomethylating agents or low-dose cytarabine. However, resistance and relapse represent major clinical challenges. Therefore, there is an unmet need to overcome resistance to current venetoclax-based strategies. We performed high-throughput drug screening to identify effective combination partners for venetoclax in AML. Overall, 64 antileukemic drugs were screened in 31 primary high-risk AML samples with or without venetoclax. Gilteritinib exhibited the highest synergy with venetoclax in FLT3 wild-type AML. The combination of gilteritinib and venetoclax increased apoptosis, reduced viability, and was active in venetoclax-azacitidine-resistant cell lines and primary patient samples. Proteomics revealed increased FLT3 wild-type signaling in specimens with low in vitro response to the currently used venetoclax-azacitidine combination. Mechanistically, venetoclax with gilteritinib decreased phosphorylation of ERK and GSK3B via combined AXL and FLT3 inhibition with subsequent suppression of the antiapoptotic protein MCL-1. MCL-1 downregulation was associated with increased MCL-1 phosphorylation of serine 159, decreased phosphorylation of threonine 161, and proteasomal degradation. Gilteritinib and venetoclax were active in an FLT3 wild-type AML patient-derived xenograft model with TP53 mutation and reduced leukemic burden in 4 patients with FLT3 wild-type AML receiving venetoclax-gilteritinib off label after developing refractory disease under venetoclax-azacitidine. In summary, our results suggest that combined inhibition of FLT3/AXL potentiates venetoclax response in FLT3 wild-type AML by inducing MCL-1 degradation. Therefore, the venetoclax-gilteritinib combination merits testing as a potentially active regimen in patients with high-risk FLT3 wild-type AML.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood.2021014241 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of FLT3-ITD Mutation, PI3K/AKT Pathway, and Leukemia Stem Cells in D3A7 Induction therapy - the Outcomes of Adult Indonesian Patients with Acute Myeloid Leukemia.
Acta Med Acad
August 2024
Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Objective: This cohort study aimed to examine the impact of the FLT3-ITD mutation on the downstream signaling pathway of PI3K/AKT pathway, the percentage of leukemia stem cells, and the survival of patients receiving D3A7 induction therapy.
Method: Bone marrow mononuclear cells were collected from 20 adult AML patients who had completed D3A7 induction therapy at Cipto Mangunkusumo National General Hospital and Dharmais Cancer Hospital. FLT3-ITD gene mutation was examined by the PCR-sequencing method.
The Clinical Impact of NPM1 Mutations and the Effect of Concurrent Mutations in Acute Myeloid Leukemia: Unraveling the Prognostic Significance.
Health Sci Rep
December 2024
Department of Molecular Biology and Biotechnology, Human Genetics Division Atomic Energy Commission Damascus Syria.
Article Synopsis
- Nucleophosmin (NPM1) gene mutations are found in 30%-35% of acute myeloid leukemia (AML) patients, with higher prevalence (50%-60%) among those with a normal karyotype.
- In a study involving 100 newly diagnosed Syrian AML patients, 22% exhibited NPM1 mutations, primarily of type A, and their presence was linked to worse outcomes, such as higher mortality rates and increased bone marrow blast percentages.
- These findings highlight the importance of assessing NPM1 mutations for better prognosis and tailored treatment strategies in AML patients with normal karyotypes.
PRDM16 Induces Methylation of FLT3 to Promote FLT3-ITD Signaling and Leukemia Progression.
Cancer Res
November 2024
1. Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China. 2. Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui, 230001, China. 3. Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, Anhui, 230001, China., Hefei, Anhui, China.
Internal tandem duplication (ITD) in the FMS-like receptor tyrosine kinase-3 (FLT3) is one of the most frequent mutations in acute myeloid leukemia (AML) and is associated with poor prognosis. FLT3-ITD mutations result in endoplasmic reticulum (ER) retention and constitutive autophosphorylation of FLT3. The PR/SET domain 16 (PRDM16) is highly expressed in FLT3-ITD+ AML patients, suggesting it might play a role in leukemogenesis.
View Article and Find Full Text PDFExploring the Prevalence and Prognostic Impact of Wilms Tumor 1 Exon 7 Mutation Status with Combinations of FLT3-ITD and NPM1 Mutations as Potential Molecular Biomarkers in Acute Myeloid Leukemia Patients with Normal Cytogenetics.
Asian Pac J Cancer Prev
October 2024
Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram, University of Kerala, India.
Article Synopsis
- This study investigates the effects of specific genetic mutations (FLT3-ITD, NPM1, WT1) on the outcomes of patients with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML), finding notable survival differences based on NPM1 mutation status.
- Out of 150 patients analyzed, 12.6% had WT1 mutations, and relationships were identified between mutation presence and certain clinical factors, like LDH and hemoglobin levels; however, correlations with overall survival were not consistently significant.
- The results indicate that assessing NPM1 and FLT3-ITD mutations at diagnosis can help predict patient prognosis in AML; further research with larger groups could provide deeper insights
and study of FLT3 inhibitors and their application in acute myeloid leukemia.
Mol Med Rep
December 2024
Biomedicine and Ecology Molecular Markers Laboratory, Department of Cellular and Molecular Biology, Biological and Agricultural Sciences Campus, University of Guadalajara, Zapopan, Jalisco 44600, Mexico.
Article Synopsis
- Acute myeloid leukemia (AML) is a common blood cancer in adults, often complicated by mutations in the FLT3 receptor that lead to poor patient outcomes.
- This study investigated how four tyrosine kinase inhibitors (TKIs) interact with both normal and mutated FLT3 receptors, revealing that second-generation TKIs have a stronger binding affinity.
- The findings suggest that the second-generation TKIs gilteritinib and quizartinib effectively target AML cells with FLT3 mutations, while sparing healthy cells, indicating potential for better therapeutic options in treating AML.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!